Literature DB >> 12415323

Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy.

Sucharita J Mistry1, George F Atweh.   

Abstract

Stathmin is a member of a novel class of microtubule-destabilizing proteins that regulate the dynamics of microtubule polymerization and depolymerization. Stathmin promotes microtubule depolymerization during interphase and late mitosis. This microtubule depolymerizing activity of stathmin is regulated by changes in its level of phosphorylation that occur during cell cycle progression. These modifications allow it to play a critical role in the regulation of the dynamic equilibrium of microtubules during different phases of the cell cycle. Stathmin is expressed at high levels in a wide variety of human cancers. Inhibition of stathmin expression in malignant cells interferes with their orderly progression through the cell cycle and abrogates their transformed phenotype. Thus, stathmin provides an attractive molecular target for disrupting the mitotic apparatus and arresting the growth of malignant cells. In this review, we describe the current understanding of the role of stathmin in the regulation of the mitotic spindle and discuss its potential as a therapeutic target of cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12415323

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  21 in total

Review 1.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

2.  Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells.

Authors:  Yunlong Lei; Kai Huang; Cong Gao; Quek Choon Lau; Hua Pan; Ke Xie; Jingyi Li; Rui Liu; Tao Zhang; Na Xie; Huey Shan Nai; Hong Wu; Qiang Dong; Xia Zhao; Edouard C Nice; Canhua Huang; Yuquan Wei
Journal:  Mol Cell Proteomics       Date:  2011-05-27       Impact factor: 5.911

3.  Stathmin is a potential molecular marker and target for the treatment of gastric cancer.

Authors:  Xiaolin Liu; Hairong Liu; Jing Liang; Beibei Yin; Junjuan Xiao; Junwei Li; Dongfeng Feng; Yan Li
Journal:  Int J Clin Exp Med       Date:  2015-04-15

4.  Epstein-Barr virus-encoded LMP1 triggers regulation of the ERK-mediated Op18/stathmin signaling pathway in association with cell cycle.

Authors:  Xuechi Lin; Min Tang; Yongguang Tao; Lili Li; Sufang Liu; Lili Guo; Zijian Li; Xiaoqian Ma; Juan Xu; Ya Cao
Journal:  Cancer Sci       Date:  2012-04-30       Impact factor: 6.716

5.  Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression.

Authors:  Rui Wang; Ke Dong; Fang Lin; Xi Wang; Ping Gao; San-Hua Wei; Shi-Yin Cheng; Hui-Zhong Zhang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

6.  Self-organization of intracellular gradients during mitosis.

Authors:  Brian G Fuller
Journal:  Cell Div       Date:  2010-01-29       Impact factor: 5.130

7.  Increased glycogen synthase kinase-3β mRNA level in the hippocampus of patients with major depression: a study using the stanley neuropathology consortium integrative database.

Authors:  Dong Hoon Oh; Yong Chon Park; Seok Hyeon Kim
Journal:  Psychiatry Investig       Date:  2010-07-12       Impact factor: 2.505

8.  Inhibition of stathmin1 accelerates the metastatic process.

Authors:  Karin Williams; Ritwik Ghosh; Premkumar Vummidi Giridhar; Guangyu Gu; Thomas Case; Scott M Belcher; Susan Kasper
Journal:  Cancer Res       Date:  2012-08-21       Impact factor: 12.701

Review 9.  The master regulator FUBP1: its emerging role in normal cell function and malignant development.

Authors:  Lydie Debaize; Marie-Bérengère Troadec
Journal:  Cell Mol Life Sci       Date:  2018-10-20       Impact factor: 9.261

10.  Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer.

Authors:  Y Nakamura; F Tanaka; N Haraguchi; K Mimori; T Matsumoto; H Inoue; K Yanaga; M Mori
Journal:  Br J Cancer       Date:  2007-07-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.